We leverage hands-on life sciences industry experience to help clients grow strategically and create value.
Our core team combines more than 40 years of experience building, operating, and growing biotechnology companies. Our accomplishments include raising private and IPO capital, leading transactions, out-licensing and in-licensing, strategic financing, negotiating business development deals, undertaking due diligence and execution, supporting corporate mergers and acquisitions, scaling operations, serving on the boards of private and publicly held companies, and overseeing discovery, preclinical, and clinical-stage drug development programs.
Ana Radeljevic, Founder & CEO
Ana Radeljevic is the founder and CEO of Adventus Partners, a company she started in 2016. She is an expert in business strategy, corporate development, fundraising, finance, and business planning. During her 20+ year career, she has established an exceptional track record helping to build and grow more than a dozen biotechnology and pharmaceutical companies ranging from established public companies to early-stage private, as well as serving as a board member and audit chair.
As a CEO of Adventus Partners advising clients and during her hands-on operating career, she has led the closing of more than $28 billion in M&A and licensing collaborations as well as equity and debt financing, including multiple IPOs.
Recently, she was CBO of Tidal Therapeutics, where she played a pivotal role in the company’s sale to Sanofi for $460 million. Ms. Radeljevic is a board member of Merrimack Pharmaceuticals (NASDAQ: MACK) and chair of its audit and investment committee.
Earlier in her career, she was a Vice President of Corporate Finance at PerkinElmer, where she led several key acquisitions. Prior to that, she led Global Business Development and Strategic Planning at Sanofi Biosurgery and Corporate Finance at Genzyme. She started her career at Deloitte in the Audit practice and, subsequently, M&A practice. Prior to her life sciences career, Ms.Radeljevic was a professional tennis player, reaching top 200 on the WTA world ranking.
Ms. Radeljevic holds an MBA from the Whitman School of Management at Syracuse University and a BS in Business Administration from Old Dominion University. She is also a CFA charter holder and a CPA.
Howard Goldsweig, Senior Consultant
Howard Goldsweig, MD is Adventus Partners’ Senior Consultant. Dr. Goldsweig has extensive experience in research, drug development, and medical affairs in the biotechnology industry, with particular expertise in the field of oncology. Previously, Dr. Goldsweig served as an Executive Medical Director at Amgen and, prior to that, at Biovexis (acquired by Amgen). Previously, he held roles of increasing responsibility in clinical drug development at Hoffmann La Roche, Bozell Healthcare, Qualus Medical Affairs, and Averion. Prior to his executive positions in biopharma companies, Dr. Goldsweig was a faculty member at College of Physicians and Surgeons of Columbia University. He also practiced as a medical oncologist at Columbia-Presbyterian Hospital and St. Lukes-Roosevelt Medical Center.
Dr. Goldsweig received an AB in Zoology from Franklin and Marshall College and an MD from the State University of New York, Downstate Medical Center College of Medicine. He completed his residency in Internal Medicine at the affiliated hospitals of the McGill University Faculty of Medicine and his Medical Oncology fellowship at Northwestern University School of Medicine. Dr. Goldsweig is board-certified in both Oncology and Internal Medicine.
Mark Barnard, Head of Client Relations
Mark Barnard is Head of Client Relations for Adventus Partners. He brings more than 30 years of client relationship experience in applying broad knowledge of human behaviors and how to interact, negotiate, and solve complex business challenges to identify optimal solutions toward favorable outcomes and success for Adventus and its clients.